Cargando…

Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection

OBJECTIVE: To report a case of anti-IgLON5 disease unmasked by asymptomatic SARS-CoV-2 infection. BACKGROUND: Anti-IgLON5 disease is a clinically heterogeneous disease that shares features of both neurodegeneration and neuroinflammation. The onset can be insidious, posing diagnostic challenges and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoyang, Landis, Timothy, Karazanashvili, Nikoloz, Diaz, Monica M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899159/
http://dx.doi.org/10.1016/j.nerep.2023.100166
_version_ 1784882581429288960
author Li, Xiaoyang
Landis, Timothy
Karazanashvili, Nikoloz
Diaz, Monica M.
author_facet Li, Xiaoyang
Landis, Timothy
Karazanashvili, Nikoloz
Diaz, Monica M.
author_sort Li, Xiaoyang
collection PubMed
description OBJECTIVE: To report a case of anti-IgLON5 disease unmasked by asymptomatic SARS-CoV-2 infection. BACKGROUND: Anti-IgLON5 disease is a clinically heterogeneous disease that shares features of both neurodegeneration and neuroinflammation. The onset can be insidious, posing diagnostic challenges and often resulting in treatment delay. Infectious trigger was rarely reported in this disease. CASE REPORT: A 64-year-old male initially presented with 1-year history of progressive parasomnia and mild cognitive decline that precipitously worsened over the course of 1 month following asymptomatic SARS-CoV-2 infection, resulting in dysphagia, parkinsonism, weight loss and dependence on all activities of daily living. He was found to have high titer (1:3840) of anti-IgLON5 antibody in the serum, confirming the diagnosis of anti-IgLON5 disease. CONCLUSION: Anti-IgLON5 disease as a potentially reversible cause of neurodegenerative syndrome in patients with atypical features. Timely diagnosis and treatment may improve clinical outcomes. It is also worth noting that symptoms precipitously worsened following SARS-CoV-2 infection. We suspect that a COVID-19-mediated immune activation response exacerbated the underlying autoimmune encephalitis process, unmasking his symptoms.
format Online
Article
Text
id pubmed-9899159
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-98991592023-02-06 Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection Li, Xiaoyang Landis, Timothy Karazanashvili, Nikoloz Diaz, Monica M. Neuroimmunology Reports Article OBJECTIVE: To report a case of anti-IgLON5 disease unmasked by asymptomatic SARS-CoV-2 infection. BACKGROUND: Anti-IgLON5 disease is a clinically heterogeneous disease that shares features of both neurodegeneration and neuroinflammation. The onset can be insidious, posing diagnostic challenges and often resulting in treatment delay. Infectious trigger was rarely reported in this disease. CASE REPORT: A 64-year-old male initially presented with 1-year history of progressive parasomnia and mild cognitive decline that precipitously worsened over the course of 1 month following asymptomatic SARS-CoV-2 infection, resulting in dysphagia, parkinsonism, weight loss and dependence on all activities of daily living. He was found to have high titer (1:3840) of anti-IgLON5 antibody in the serum, confirming the diagnosis of anti-IgLON5 disease. CONCLUSION: Anti-IgLON5 disease as a potentially reversible cause of neurodegenerative syndrome in patients with atypical features. Timely diagnosis and treatment may improve clinical outcomes. It is also worth noting that symptoms precipitously worsened following SARS-CoV-2 infection. We suspect that a COVID-19-mediated immune activation response exacerbated the underlying autoimmune encephalitis process, unmasking his symptoms. The Authors. Published by Elsevier B.V. 2023 2023-02-05 /pmc/articles/PMC9899159/ http://dx.doi.org/10.1016/j.nerep.2023.100166 Text en © 2023 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Li, Xiaoyang
Landis, Timothy
Karazanashvili, Nikoloz
Diaz, Monica M.
Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection
title Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection
title_full Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection
title_fullStr Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection
title_full_unstemmed Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection
title_short Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection
title_sort anti-iglon5 disease exacerbated by asymptomatic sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899159/
http://dx.doi.org/10.1016/j.nerep.2023.100166
work_keys_str_mv AT lixiaoyang antiiglon5diseaseexacerbatedbyasymptomaticsarscov2infection
AT landistimothy antiiglon5diseaseexacerbatedbyasymptomaticsarscov2infection
AT karazanashvilinikoloz antiiglon5diseaseexacerbatedbyasymptomaticsarscov2infection
AT diazmonicam antiiglon5diseaseexacerbatedbyasymptomaticsarscov2infection